Cooper Companies (NASDAQ:COO) Upgraded at Barclays

Barclays upgraded shares of Cooper Companies (NASDAQ:COO) to a hold rating in a research report report published on Wednesday morning,Zacks reports.

Several other research firms also recently issued reports on COO. Mizuho set a $75.00 target price on Cooper Companies and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Robert W. Baird set a $61.00 price target on Cooper Companies and gave the company a “neutral” rating in a research report on Thursday, September 10th. William Blair lowered Cooper Companies from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 10th. Zacks Research cut Cooper Companies from a “hold” rating to a “strong sell” rating in a report on Friday, September 11th. Finally, JPMorgan Chase & Co. cut their target price on Cooper Companies from $71.00 to $58.00 and set a “neutral” rating for the company in a research note on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $68.60.

Cooper Companies Price Performance

COO opened at $54.37 on Wednesday. The firm has a 50-day moving average price of $65.28 and a 200-day moving average price of $66.65. Cooper Companies has a twelve month low of $51.01 and a twelve month high of $89.83. The company has a quick ratio of 0.73, a current ratio of 1.22 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $10.34 billion, a price-to-earnings ratio of 18.56, a PEG ratio of 2.21 and a beta of 0.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. Cooper Companies’s revenue was up .5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. Equities analysts expect that Cooper Companies will post 4.53 EPS for the current year.

Cooper Companies declared that its Board of Directors has approved a stock buyback plan on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to reacquire up to 22.7% of its stock through open market purchases. Share repurchase plans are usually a sign that the company’s board believes its stock is undervalued.

Insider Activity

In other news, Director Paul Keel purchased 4,701 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were purchased at an average price of $53.18 per share, with a total value of $249,999.18. Following the completion of the acquisition, the director owned 4,701 shares in the company, valued at $249,999.18. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Walter Rosebrough, Jr. acquired 7,000 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was acquired at an average price of $54.11 per share, for a total transaction of $378,770.00. Following the transaction, the director directly owned 17,000 shares of the company’s stock, valued at $919,870. This represents a 70.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 34,701 shares of company stock worth $1,880,039 in the last three months. Corporate insiders own 2.08% of the company’s stock.

Institutional Trading of Cooper Companies

A number of large investors have recently modified their holdings of the business. Envestnet Portfolio Solutions Inc. raised its stake in Cooper Companies by 112.8% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 15,784 shares of the medical device company’s stock valued at $1,132,000 after purchasing an additional 8,366 shares in the last quarter. HBK Investments L P bought a new position in shares of Cooper Companies in the 2nd quarter worth $31,666,000. Sequoia Financial Advisors LLC increased its holdings in shares of Cooper Companies by 290.4% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock worth $2,459,000 after buying an additional 25,504 shares during the last quarter. Tidal Investments LLC increased its holdings in shares of Cooper Companies by 281.4% in the 2nd quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock worth $5,945,000 after buying an additional 61,165 shares during the last quarter. Finally, National Pension Service raised its position in shares of Cooper Companies by 9,314.0% during the 2nd quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock valued at $37,730,000 after buying an additional 520,560 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

More Cooper Companies News

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Barclays upgraded COO to “Hold.” The move from a more negative rating removes some pressure on the shares, although “Hold” still indicates limited near-term upside in the bank’s view. Cooper Companies Stock Rating Raised to Hold at Barclays
• Positive Sentiment: Cooper’s latest earnings included an EPS beat. The company reported quarterly EPS of $1.15, above the $1.12 analyst consensus, while full-year 2026 guidance remains centered near $4.53 per share. This suggests profitability is holding up despite operational concerns. Why Is The Cooper Companies Up Since Last Earnings Report?
• Neutral Sentiment: Post-earnings trading has been relatively stable. A review of the period since the September 9 earnings report notes only a modest change in the stock, reflecting investor uncertainty after revenue of $1.07 billion came in below the $1.10 billion consensus estimate. Revenue growth was only 0.5% year over year.
• Negative Sentiment: Several law firms are investigating potential securities claims. Rosen Law Firm issued another investor notice, following separate Rosen and Pomerantz announcements, alleging that Cooper may have provided materially misleading business information. These notices do not establish wrongdoing, but they add litigation risk and can pressure the valuation. Rosen Investor Investigation
• Negative Sentiment: The consensus price target was reduced by 17.87% to MX$1,180.28. The cut signals that analysts have lowered their expectations for COO’s fair value, likely reflecting weaker growth expectations and ongoing uncertainty.

About Cooper Companies

CooperCompanies (NASDAQ: COO) is a global medical device company focused on improving vision and advancing women’s health. Its operations are organized primarily through CooperVision and CooperSurgical, which develop, manufacture and distribute products for eye care, fertility and other areas of reproductive health.

CooperVision offers a broad range of contact lenses, including lenses for nearsightedness, farsightedness, astigmatism and presbyopia. Its portfolio includes daily disposable, reusable and specialty lenses, as well as products designed to address the progression of myopia in children and adolescents.